Cargando…

New insights into the performance of human whole-exome capture platforms

Whole exome sequencing (WES) is increasingly used in research and diagnostics. WES users expect coverage of the entire coding region of known genes as well as sufficient read depth for the covered regions. It is, however, unknown which recent WES platform is most suitable to meet these expectations....

Descripción completa

Detalles Bibliográficos
Autores principales: Meienberg, Janine, Zerjavic, Katja, Keller, Irene, Okoniewski, Michal, Patrignani, Andrea, Ludin, Katja, Xu, Zhenyu, Steinmann, Beat, Carrel, Thierry, Röthlisberger, Benno, Schlapbach, Ralph, Bruggmann, Rémy, Matyas, Gabor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477645/
https://www.ncbi.nlm.nih.gov/pubmed/25820422
http://dx.doi.org/10.1093/nar/gkv216
_version_ 1782377786974928896
author Meienberg, Janine
Zerjavic, Katja
Keller, Irene
Okoniewski, Michal
Patrignani, Andrea
Ludin, Katja
Xu, Zhenyu
Steinmann, Beat
Carrel, Thierry
Röthlisberger, Benno
Schlapbach, Ralph
Bruggmann, Rémy
Matyas, Gabor
author_facet Meienberg, Janine
Zerjavic, Katja
Keller, Irene
Okoniewski, Michal
Patrignani, Andrea
Ludin, Katja
Xu, Zhenyu
Steinmann, Beat
Carrel, Thierry
Röthlisberger, Benno
Schlapbach, Ralph
Bruggmann, Rémy
Matyas, Gabor
author_sort Meienberg, Janine
collection PubMed
description Whole exome sequencing (WES) is increasingly used in research and diagnostics. WES users expect coverage of the entire coding region of known genes as well as sufficient read depth for the covered regions. It is, however, unknown which recent WES platform is most suitable to meet these expectations. We present insights into the performance of the most recent standard exome enrichment platforms from Agilent, NimbleGen and Illumina applied to six different DNA samples by two sequencing vendors per platform. Our results suggest that both Agilent and NimbleGen overall perform better than Illumina and that the high enrichment performance of Agilent is stable among samples and between vendors, whereas NimbleGen is only able to achieve vendor- and sample-specific best exome coverage. Moreover, the recent Agilent platform overall captures more coding exons with sufficient read depth than NimbleGen and Illumina. Due to considerable gaps in effective exome coverage, however, the three platforms cannot capture all known coding exons alone or in combination, requiring improvement. Our data emphasize the importance of evaluation of updated platform versions and suggest that enrichment-free whole genome sequencing can overcome the limitations of WES in sufficiently covering coding exons, especially GC-rich regions, and in characterizing structural variants.
format Online
Article
Text
id pubmed-4477645
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44776452015-06-29 New insights into the performance of human whole-exome capture platforms Meienberg, Janine Zerjavic, Katja Keller, Irene Okoniewski, Michal Patrignani, Andrea Ludin, Katja Xu, Zhenyu Steinmann, Beat Carrel, Thierry Röthlisberger, Benno Schlapbach, Ralph Bruggmann, Rémy Matyas, Gabor Nucleic Acids Res Methods Online Whole exome sequencing (WES) is increasingly used in research and diagnostics. WES users expect coverage of the entire coding region of known genes as well as sufficient read depth for the covered regions. It is, however, unknown which recent WES platform is most suitable to meet these expectations. We present insights into the performance of the most recent standard exome enrichment platforms from Agilent, NimbleGen and Illumina applied to six different DNA samples by two sequencing vendors per platform. Our results suggest that both Agilent and NimbleGen overall perform better than Illumina and that the high enrichment performance of Agilent is stable among samples and between vendors, whereas NimbleGen is only able to achieve vendor- and sample-specific best exome coverage. Moreover, the recent Agilent platform overall captures more coding exons with sufficient read depth than NimbleGen and Illumina. Due to considerable gaps in effective exome coverage, however, the three platforms cannot capture all known coding exons alone or in combination, requiring improvement. Our data emphasize the importance of evaluation of updated platform versions and suggest that enrichment-free whole genome sequencing can overcome the limitations of WES in sufficiently covering coding exons, especially GC-rich regions, and in characterizing structural variants. Oxford University Press 2015-06-23 2015-03-27 /pmc/articles/PMC4477645/ /pubmed/25820422 http://dx.doi.org/10.1093/nar/gkv216 Text en © The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methods Online
Meienberg, Janine
Zerjavic, Katja
Keller, Irene
Okoniewski, Michal
Patrignani, Andrea
Ludin, Katja
Xu, Zhenyu
Steinmann, Beat
Carrel, Thierry
Röthlisberger, Benno
Schlapbach, Ralph
Bruggmann, Rémy
Matyas, Gabor
New insights into the performance of human whole-exome capture platforms
title New insights into the performance of human whole-exome capture platforms
title_full New insights into the performance of human whole-exome capture platforms
title_fullStr New insights into the performance of human whole-exome capture platforms
title_full_unstemmed New insights into the performance of human whole-exome capture platforms
title_short New insights into the performance of human whole-exome capture platforms
title_sort new insights into the performance of human whole-exome capture platforms
topic Methods Online
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477645/
https://www.ncbi.nlm.nih.gov/pubmed/25820422
http://dx.doi.org/10.1093/nar/gkv216
work_keys_str_mv AT meienbergjanine newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT zerjavickatja newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT kellerirene newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT okoniewskimichal newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT patrignaniandrea newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT ludinkatja newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT xuzhenyu newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT steinmannbeat newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT carrelthierry newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT rothlisbergerbenno newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT schlapbachralph newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT bruggmannremy newinsightsintotheperformanceofhumanwholeexomecaptureplatforms
AT matyasgabor newinsightsintotheperformanceofhumanwholeexomecaptureplatforms